Mykell Barnacle1, Mark A Strand2, Amy Werremeyer3, Brody Maack3, Natasha Petry3. 1. School of Nursing, North Dakota State University, Fargo, North Dakota, USA (Dr Barnacle) 2. Department of Pharmacy Practice and Masters in Public Health Program, North Dakota State University, Fargo, North Dakota, USA (Dr Strand) 3. Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota, USA (Dr Werremeyer, Dr Maack, Dr Petry)
Abstract
PURPOSE: Evidence-based guidelines recommend regular depression screening among individuals with type 2 diabetes mellitus (T2DM). The purpose of this study is to examine depression screening patterns among a primary care population with T2DM, through use of the Patient Health Questionnaire-9 (PHQ-9). METHODS: In total, 1817 patients with T2DM were analyzed through a retrospective observational study at 2 sites, a regional health center and a federally qualified health center (FQHC). The T2DM sample was divided into those with and without a major depressive disorder (MDD) diagnosis. Depression screening rates and depression severity were assessed through the PHQ-9. RESULTS: Both sites had higher rates of PHQ-9 screening among individuals with a history of MDD (64.82%) vs those without MDD (11.39%). Individuals from the FQHC without a history of depression had a higher mean PHQ-9 score (10.11) than those with a previous MDD diagnosis at both RHS and FQHC (7.16 and 9.85, respectively). CONCLUSIONS: Depression screening rates among individuals with diabetes and no history of MDD were remarkably low. Patients with diabetes but no MDD diagnosis who sought health care at a FQHC clinic had more depressive symptoms than those with a history of MDD at both sites. Individuals with diabetes and who have a MDD diagnosis are much more likely to receive regular depression screening than those without MDD, which leaves a substantial proportion of patients with undetected depression. Depression screening must be enhanced for all individuals with diabetes, particularly for low-income individuals and those without a previous diagnosis of MDD.
PURPOSE: Evidence-based guidelines recommend regular depression screening among individuals with type 2 diabetes mellitus (T2DM). The purpose of this study is to examine depression screening patterns among a primary care population with T2DM, through use of the Patient Health Questionnaire-9 (PHQ-9). METHODS: In total, 1817 patients with T2DM were analyzed through a retrospective observational study at 2 sites, a regional health center and a federally qualified health center (FQHC). The T2DM sample was divided into those with and without a major depressive disorder (MDD) diagnosis. Depression screening rates and depression severity were assessed through the PHQ-9. RESULTS: Both sites had higher rates of PHQ-9 screening among individuals with a history of MDD (64.82%) vs those without MDD (11.39%). Individuals from the FQHC without a history of depression had a higher mean PHQ-9 score (10.11) than those with a previous MDD diagnosis at both RHS and FQHC (7.16 and 9.85, respectively). CONCLUSIONS:Depression screening rates among individuals with diabetes and no history of MDD were remarkably low. Patients with diabetes but no MDD diagnosis who sought health care at a FQHC clinic had more depressive symptoms than those with a history of MDD at both sites. Individuals with diabetes and who have a MDD diagnosis are much more likely to receive regular depression screening than those without MDD, which leaves a substantial proportion of patients with undetected depression. Depression screening must be enhanced for all individuals with diabetes, particularly for low-income individuals and those without a previous diagnosis of MDD.
Authors: Michelle D Owens-Gary; Xuanping Zhang; Shawn Jawanda; Kai McKeever Bullard; Pamela Allweiss; Bryce D Smith Journal: J Gen Intern Med Date: 2018-10-22 Impact factor: 5.128
Authors: Tamara K Oser; Sean M Oser; Jessica A Parascando; Danielle Hessler-Jones; Christopher N Sciamanna; Kerri Sparling; Donald Nease; Michelle L Litchman Journal: Curr Diab Rep Date: 2020-02-20 Impact factor: 4.810
Authors: Kaitlyn E Brodar; Annette M La Greca; Rafael O Leite; Daniella Marchetti; Manuela Jaramillo; Maria Luzuriaga; Rajesh Garg; Patrice Saab Journal: J Clin Psychol Med Settings Date: 2022-03-22